Why the study?
Does blockade of NF-kappaB activation improve cardiac function and survival in a mouse model of TNF-alpha-induced cardiomyopathy?
Does blockade of NF-kappaB activation improve cardiac function and survival in a mouse model of TNF-alpha-induced cardiomyopathy?
Blockade of NF-κB activation improves cardiac function and survival in a mouse model of TNF-α-induced cardiomyopathy by suppressing MMP-9, suggesting a potential therapeutic target for heart failure.
Answers are grounded in this paper and cite their sources.
p50 disruption benefits TNF-α cardiomyopathy mice via MMP-9; leaves open translation to human heart failure therapy.
OBJECTIVE: NF-kappaB, a key transcription factor that regulates inflammatory processes, has been shown to be activated in the failing human heart with enhanced expression of proinflammatory cytokines. In the present study, we assessed the hypothesis that cardiotoxic effects of proinflammatory cytokines are mediated by the activation of NF-kappaB. METHODS: Transgenic mice with cardiac-specific overexpression of TNF-alpha were used as a model of cytokine-induced cardiomyopathy. To block the activation of NF-kappaB, transgenic mice (TG/p50(+/+)) were crossed with knockout mice in which the p50 subunit of NF-kappaB was disrupted (WT/p50(-/-)). RESULTS: The electrophoretic mobility shift assay demonstrated that NF-kappaB was activated in the myocardium of TG/p50(+/+) mice, while it was completely abolished in TG/p50(-/-) mice. Male TG mice died of congestive heart failure earlier than females, where the disruption of the p50 subunit significantly improved the survival. Compared with TG/p50(+/+) mice, TG/p50(-/-) mice showed a significant reduction of ventricular dilatation and hypertrophy with preserved fractional shortening. Although the myocardial expression of proinflammatory cytokines or infiltration of inflammatory cells was not affected, increased expression and activity of MMP-9 were significantly suppressed in TG/p50(-/-) mice. CONCLUSION: Blockade of NF-kappaB activation did not ameliorate myocardial inflammation but improved cardiac function and survival in male TNF-alpha TG mice. An inhibition of NF-kappaB may be a new therapeutic strategy for cardiac remodeling and heart failure, especially when proinflammatory cytokines are activated.
No takes yet. Share an insight, caveat, or question.
Kawamura et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: